Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT), a commercial-stage biotechnology company with a market capitalization of $428 million specializing in mRNA therapeutics and vaccines, stands at a ...
Discover how mRNA-based blood clots offer a promising new treatment for osteoarthritis, potentially surpassing traditional ...
Zacks.com on MSN10d
Moderna (MRNA) Increases Despite Market Slip: Here's What You Need to KnowModerna (MRNA) closed the latest trading day at $41.66, indicating a +0.6% change from the previous session's end. The stock outperformed the S&P 500, which registered a daily loss of 1.46%. Elsewhere ...
The mRNA-1273.815 vaccine provided significant protection against COVID-19-related hospitalizations and medically attended COVID-19 among US adults.
Russia cancer vaccine could receive approval by August allowing treatment to begin the head of the Gamaleya Research ...
WVE-007 is a novel, long-acting GalNAc-siRNA targeting INHBE mRNA – a genetically validated target that provides a new approach for healthy, ...
Meet the woman leading vaccine innovation in Senegal to fight Rift Valley fever and empower Africa’s next generation of ...
WVE-007 is a novel, long-acting GalNAc-siRNA targeting INHBE mRNA - a genetically validated target that provides a new approach for healthy, sustainable weight loss (fat loss with muscle preservation) ...
Despite continued underperformance in 2024, the biotech sector enters 2025 with a brighter outlook driven by groundbreaking ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback